Menu
Prostate Tissue Ablation with HIFU has been used and studied around the world for more than 20 years. Today, more than 100 peer-reviewed publications constitute a solid body of evidence for HIFU prostate ablation in the management of Prostate Cancer.
2022 – European Urology
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience
D. Reddy, et al.
“Focal HIFU in carefully selected patients with clinically significant prostate cancer, with six and three of ten patients having, respectively, intermediate- and high-risk cancer, has good cancer control in the medium term.”
Link – https://www.sciencedirect.com/science/article/abs/pii/S0302283822000069?via%3Dihub
2021 – Prostate Cancer and Prostatic Diseases
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study
T. Shah, et al.
“In patients with non-metastatic low- intermediate prostate cancer, oncological outcomes over 8 years were similar between focal therapy and radical prostatectomy.”
Link – https://www.nature.com/articles/s41391-020-00315-y
2021 – Prostate Cancer and Prostatic Diseases
Oncological and functional outcome after partial prostate HIFU ablation with Focal-One : a prospective single-center study
M. Dellabella, et al.
“189 prospectively enrolled prostate cancer patients underwent focal ablation with Focal One Robotic. “Index lesion HIFU ablation demonstrated satisfactory early oncological outcome […]. Urinary function was well preserved.”
2020 – Journal of Urology
Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer
B. Nahar, et al.
“Focal high intensity focused ultrasound is a safe and effective treatment for patients with localized clinically significant prostate cancer with acceptable short-term oncologic and functional outcomes. The complications are minimal and patient selection is essential.”
Link – https://www.auajournals.org/doi/10.1097/JU.0000000000001015
2020 – Journal of Urology
High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series
A. Abreu, et al.
“Short-term results of focal high intensity focused ultrasound indicate safety, excellent potency and continence preservation, and adequate short-term prostate cancer control. Radical treatment was avoided in 91% of men at 2 years”
Link – https://www.auajournals.org/doi/10.1097/JU.0000000000001126
2019 – British Journal of Urology International
Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer
A. Stabile, et al.
“Focal HIFU for PCa is a feasible therapeutic strategy, with acceptable survival and oncological results and a reduction in the 5-year retreatment rates over the last decade. Re-do focal treatment is a feasible technique whose functional and oncological outcomes have still to be evaluated.”
Link – https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.14710
2018 – Journal of EndoUrology
Focal Treatment for Unilateral Prostate Cancer Using High-Intensity Focal Ultrasound: A Comprehensive Study of Pooled Data
S. Albisinni, et al.
“In the 366 analyzed cases, […] at one year after HIFU, negative biopsy rate for clinically significant PCa was 87% (79–96), whereas salvage treatment-free survival rate was 92% (85–98). Regarding functional outcomes, reported potency rates were 74% (64–84), and continence 96% (91–100)…”
Link – https://www.liebertpub.com/doi/10.1089/end.2018.0130
2018 – European Urology
A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
S. Guillaumier, et al.
“In this multicentre study of 625 patients undergoing focal therapy using high-intensity focused ultrasound (HIFU), failure-free survival, metastasis-free survival, cancer-specific survival, and overall survival were 88%, 98%, 100%, and 99%, respectively. Urinary incontinence (any pad use) was 2%. Focal HIFU therapy for patients with clinically significant prostate cancer that has not spread has a low probability of side effects and is effective at 5 yr.”
Link – https://www.sciencedirect.com/science/article/pii/S0302283818304317?via%3Dihub
2017 – British Journal of Urology International
Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients
S. Crouzet, et al.
Retrospective study of 418 patients with local recurrent disease after EBRT treated with Salvage HIFU in 9 different centers in Europe. “The OS, CSS and MFS rates at 7 years were 72%, 82% and 81%, respectively.”
Link – https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.13766
2017 – Journal of EndoUrology
Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis
S. Albisinni, et al.
“In this matched pair analysis, HIFU hemiablation was comparable to RALP in controlling localized unilateral PCa, with no significant differences in the need for salvage therapies. HIFU was also associated to significantly better functional outcomes.”
2016 – European Urology
Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients
P. Rischmann, et al.
“At 1 yr, HIFU-hemiablation was efficient with 95% absence of clinically significant cancer associated with low morbidity and preservation of quality of life. Radical treatment-free survival rate was 89% at 2 yr.”
Link – https://www.sciencedirect.com/science/article/abs/pii/S0302283816306790?via%3Dihub
2015 – Prostate Cancer and Prostatic Diseases
A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer
R. van Velthoven, et al.
“Hemiablation HIFU therapy, delivered with intention to treat, for carefully selected patients affords mid-term promising functional and oncological outcomes.”
Link – https://www.nature.com/articles/pcan201555
2015 – European Urology
Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes
E. Cordeiro, et al.
“This study showed that high-intensity focused ultrasound hemiablation in selected patients with unilateral organ-confined prostate cancer can be used for satisfactory cancer control with minimal effect on genitourinary functions.”
Link – https://www.sciencedirect.com/science/article/abs/pii/S0302283815005217?via%3Dihub
2014 – British Journal of Urology
Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study
E. Baco, et al.
“Hemi-Salvage HIFU is a feasible therapeutic option in patients with unilateral radiorecurrent prostate cancer, which offers limited urinary and rectal morbidity, and preserves health-related quality of life.”
Link – https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.12545
2013 – Journal of Urology
Evolution and Outcomes of 3 MHz High Intensity Focused Ultrasound Therapy for Localized Prostate Cancer During 15 Years
S. Thüroff, et al.
“Of 704 study patients 78.5% had intermediate or high risk disease. Mean followup was 5.3 years (range 1.3 to 14). Cancer specific survival was 99%, metastasis-free survival was 95%, and 10-year salvage treatment-free rates were 98% in low risk, 72% in intermediate risk and 68% in high risk patients.”
Link – https://www.auajournals.org/doi/10.1016/j.juro.2013.02.010
2013 – British Journal of Urology
Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer
R. Ganzer, et al.
“The study demonstrates the efficacy and safety of HIFU for localized PCa. HIFU is a therapeutic option for patients of advanced age, in the low- or intermediate-risk groups, and with a life expectancy of ~10 years.”
Link – none
2013 – European Urology
Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients
S. Crouzet, et al.
“HIFU is a potentially effective treatment of localized PCa, with a low PCa-specific mortality rate and a high MFSR at 10 yr as well as acceptable morbidity.”
Link – https://www.sciencedirect.com/science/article/abs/pii/S0302283813004247?via%3Dihub
2021 – European Urology Focus
Oncological Long-term Outcome After Whole-gland High-intensity Focused Ultrasound for Prostate Cancer—21-yr Follow-up
J. Bründl, et al.
“Long-term data after whole-gland high-intensity focused ultrasound (HIFU) therapy are crucial to prove its oncological efficacy, and may help derive implications for focal treatment strategies and patient selection. In this context, whole-gland HIFU achieved good long-term cancer control up to 21 yr in low- and intermediate-risk prostate cancer (PCa) patients.”
Link – https://www.eu-focus.europeanurology.com/article/S2405-4569(20)30318-7/fulltext
Why Physician are Adding FocalOne to their Prostate Cancer Management Programs and how Focal HIFU Therapy fills an important gap in Prostate Cancer management program. Visit the Physician section to review 154 peer-reviewed publications regarding Focal HIFU Therapy.
Discover the Patient Benefits of HIFU and how you can change your prostate health without changing your life. Focal One HIFU Prostate Tissue Ablation allow patients maintain their quality of life with minimal side-effects. To find a HIFU Center near you, visit the Patient section.
The 2022 SUO Annual Meeting is here. Experience the Leading Prostate Focal Therapy Controlled by Urologists. Join us as Urologists from around the globe will be attending the 2022 SUO Annual Scientific Meeting in Urologic Oncology on the San Diego waterfront.